Literature DB >> 18381115

Gynecologic malignancies.

Bradford P Whitcomb1.   

Abstract

The pioneers in the field of gynecologic oncology set out to establish an evidence-based approach to the care of women with gynecologic cancer, combining the modalities of surgery, chemotherapy, and radiation. Quality of life has become the cornerstone of care for these patients, in addition to advancing survival through surgical technology, collaborative research trials, and molecular approaches to early diagnosis and management. This article addresses the epidemiology, screening, preventive strategies, diagnosis, staging, surgical care, adjuvant therapy, prognosis, and recurrence management of three common gynecologic malignancies encountered in the operating arena: endometrial, cervical, and vulvar cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18381115     DOI: 10.1016/j.suc.2008.01.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  6 in total

1.  Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.

Authors:  Omar Habeeb; Lee Goodglick; Robert A Soslow; Rajiv G Rao; Lynn K Gordon; Osvaldo Schirripa; Steve Horvath; Jonathan Braun; David B Seligson; Madhuri Wadehra
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

2.  To operate or to radiate: the added value of the maximal standardized uptake value in PET-FDG in cervical cancer patients.

Authors:  Itamar Netzer; Shehrban Sobeh; Zohar Keidar; Lior Lowenstein; Ofer Lavie; Rahamim Ben Yosef; Amnon Amit
Journal:  Med Oncol       Date:  2013-04-03       Impact factor: 3.064

3.  Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.

Authors:  Seung-Hyun Jung; Youn Jin Choi; Min Sung Kim; In-Pyo Baek; Sung Hak Lee; Ah Won Lee; Soo Young Hur; Tae-Min Kim; Sug Hyung Lee; Yeun-Jun Chung
Journal:  Oncotarget       Date:  2015-02-28

4.  Preliminary results of modified interstitial MIAMI brachytherapy applicator for treatment of upper and apical vaginal tumors.

Authors:  Payal Patel; Christopher Deufel; Michael Haddock; Ivy Petersen
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

5.  Common mitochondrial polymorphisms as risk factor for endometrial cancer.

Authors:  Anna M Czarnecka; Aleksandra Klemba; Andrzej Semczuk; Katarzyna Plak; Barbara Marzec; Tomasz Krawczyk; Barbara Kofler; Pawel Golik; Ewa Bartnik
Journal:  Int Arch Med       Date:  2009-10-28

6.  EMP2 is a novel therapeutic target for endometrial cancer stem cells.

Authors:  M H Kiyohara; C Dillard; J Tsui; S R Kim; J Lu; D Sachdev; L Goodglick; M Tong; V F Torous; C Aryasomayajula; W Wang; P Najafzadeh; L K Gordon; J Braun; S McDermott; M S Wicha; M Wadehra
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 8.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.